GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

DH Enchantment ENMI · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

+100.00%

Close of 2 Nov 2026, in USD

About DH Enchantment

Its shares trade under the ticker ENMI. It has been listed since 29 October 2004. In the fiscal year to 31 March 2024, it reported revenue of $686 and a net loss of $156,153. At that date it held total assets of $3,814 and shareholders' equity of −$985,964.

DH Enchantment, Inc. is a holding company which has no operation of its own. The company is headquartered in Las Vegas, Nevada. The company went IPO on 2004-10-29. The firm conducts its operations through its Hong Kong subsidiary, Ho Shun Yi Limited (HSY). HSY is engaged primarily in the sale and distribution of Coronavirus Disease 2019 (COVID-19) rapid antigen tester sets produced by third parties. HSY primarily sells its products primarily in Hong Kong. HSY's wholly owned subsidiary is DH Investment Group Limited, which is an investment holding company. The firm operates its testing business through DH Investment Group Limited.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
29 Oct 2004
Employees
3

Leadership

Pay as last reported

  • Mr. Cheuk Yin CheungChief Executive Officer, Chief Financial Officer, Company Secretary, Director, since 2024

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • DH Enchantment Inc has a Hong Kong subsidiary HSY selling rapid antigen testers in Hong Kong.
  • HSY's wholly owned subsidiary DH Investment Group Limited manages the testing business operations.
  • The company has a simple structure with only three employees and a clear focus on testing products.

Weaknesses

  • The company has only three employees which limits operational capacity.
  • HSY's reliance on third-party rapid antigen testers may lead to supply chain issues.
  • The firm's operations are limited to Hong Kong with no international expansion.

Opportunities

  • The global demand for rapid antigen testers could increase the company's market share.
  • Expanding into other Asian markets could leverage HSY's existing distribution network.
  • The company could partner with more third-party producers to diversify product offerings.

Threats

  • The pandemic may decline, reducing demand for rapid antigen testers.
  • Regulatory changes in Hong Kong could affect the sale of medical products.
  • Competition from established medical suppliers could erode market position.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.